title: Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas.
abstract: The World Health Organization-European Organization for Research and Treatment of Cancer has individualized three main categories among the primary cutaneous B cell lymphoma (PCBCL): leg-type primary cutaneous large B cell lymphoma (PCLBCL leg type), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous marginal zone lymphoma (PCMZL). The genetic features of 21 PCBCL cases (six PCLBCL leg type four PCFCL large cells, seven PCFCL small cells, and four PCMZL) were investigated by comparative genomic hybridization (CGH array). Fluorescent in situ hybridization (FISH) analysis was performed to confirm CGH array data and to detect lymphoma-associated gene rearrangements. p14(ARF)/p16(INK4a) CDKN2A gene quantification, methylation analysis, and immunohistochemical detection were also performed. CGH array showed a higher number of recurrent genetic imbalances in PCLBCL leg type (mean 62) than in PCFCL large cells (mean 34). PCFCL small cells and PCMZL exhibited fewer chromosomal alterations (mean 24 and 9). FISH analysis provided concordant results with CGH array data in 97% (98 of 101) assays and demonstrated a t(8;14)(q24;q32) in two of six PCLBCL leg type. Recurrent deletions in 9p21 (p14(ARF)/p16(INK4a)CDKN2A) were a constant finding in PCLBCL leg type (six of six). Conversely, PCFCL large cells exhibited recurrent 1p36 deletions (four of four) without deletion in 9p21 (zero of four). The diagnostic and prognostic impact of the p16(INK4a)CDKN2A gene status in PCBCL should therefore be confirmed on a larger series.
authors.affiliation: EA 2406 Histologie et Pathologie Moléculaire des Tumeurs, Université Victor Segalen, Batiment 3B, 2ème étage, 146 rue Leo saignat, 33076 Bordeaux Cedex, France. MA.Belaud-Rotureau@histo.u-bordeaux2.fr
authors.forename: Marc-Antoine
authors.initials: MA
authors.lastname: Belaud-Rotureau
authors.forename: Virginie
authors.initials: V
authors.lastname: Marietta
authors.forename: Beatrice
authors.initials: B
authors.lastname: Vergier
authors.forename: Guillaume
authors.initials: G
authors.lastname: Mainhaguiet
authors.forename: Michelle
authors.initials: M
authors.lastname: Turmo
authors.forename: Yamina
authors.initials: Y
authors.lastname: Idrissi
authors.forename: Jacky
authors.initials: J
authors.lastname: Ferrer
authors.forename: Marie
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: Pierre
authors.initials: P
authors.lastname: Dubus
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Merlio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D005260:Female; D020868:Gene Silencing; D019942:Genes, p16 / Q000502:physiology*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016393:Lymphoma, B-Cell / Q000235:genetics*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000235:genetics*; D025803:Tumor Suppressor Protein p14ARF / Q000235:genetics
chemical_list: D025803:Tumor Suppressor Protein p14ARF